madman
Super Moderator
Table 1. Serum TT and lipids at baseline and final assessment in the total cohort stratified by TU and statin treatment.
Table. 2 Lipid values at baseline and follow-up (24. 48, 72 and 96 months) in men with a follow-up duration ≥96 monthns stratified by TU and statin therapy.
5 Conclusions
In this analysis, we have shown that TC, LDL-cholesterol and TG values gradually worsen in men with adult-onset TD, a syndrome associated with increased risk of CVD and mortality, if the testosterone deficit is not corrected. Reassuringly, normalisation of serum TT leads to improvement in the lipid profiles, with most of this improvement occurring within the initial 24 months of therapy. Serum LDL-cholesterol also independently was associated with all-cause mortality, this is not surprising given the widely accepted lipid hypothesis. Baseline serum LDL-cholesterol and TG levels predicted the change in values in the men on TU. We finally calculated the relative risk reduction for CVD based on the findings of the CTT Collaboration in theTU-treated men [4, 5]. We estimate that the median relative risk reduction for CVD to be 39.2% in the total TU-treated study, in the statin-untreated and statin-treated subgroups the figures were calculated to be 32.8% and4 3.5%, respectively. These figures assume greater significance as our cohort of men with adult-onset TD are at high risk of CVD. Despite the relative risk reduction being impressive, it could perhaps be an underestimate as we are not taking the decrease in serum TG into account. However, it must be emphasised that our relative risk reduction estimates are based on findings from study cohorts possessing very different baseline characteristics, hence further studies in adult-onsetTD must have a long follow-up with CVD included as a primary outcome.
